

**REPLACED BY
ART 34 AMDT.**

99/19 PH ASTA Medica AG

- 14 -

Pat nt claims:

1. Pharmaceutical preparation comprising, separately or together, an efficacious amount of (i) a soft steroid and/or a pharmaceutically tolerable ester thereof and (ii) at least one β_2 adrenoceptor agonist for simultaneous, sequential or separate administration by inhalation in the treatment of airway disorders in mammals.
5
- 10 2. Pharmaceutical preparation according to Claim 1, characterized in that the soft steroid is loteprednol or a pharmaceutically tolerable ester thereof.
- 15 3. Pharmaceutical preparation according to Claim 1 or 2, characterized in that the soft steroid is loteprednol etabonate.
- 20 4. Pharmaceutical preparation according to one of Claims 1 to 3, characterized in that the β_2 adrenoceptor agonist is selected from the group consisting of salbutamol, reproterol, salmeterol, formoterol and their pharmaceutically tolerable salts.
25
5. Pharmaceutical preparation according to one of Claims 1 to 4, characterized in that it contains (i) loteprednol and (ii) formoterol.
- 30 6. Pharmaceutical preparation according to one of Claims 1 to 4, characterized in that it contains (i) loteprednol and (ii) salmeterol.
- 35 7. Pharmaceutical preparation according to one of Claims 1 to 4, characterized in that it contains (i) loteprednol and (ii) reproterol.

8. Medicament for the treatment of allergies and/or airway disorders, comprising an efficacious amount of (i) loteprednol and (ii) at least one β_2 sympathomimetic in a fixed or free combination, if appropriate together with customary excipients or vehicles.

5
9. Process for the production of a medicament for the treatment of allergies and/or airway disorders, comprising the active compound loteprednol and at least one β_2 sympathomimetic, characterized in that loteprednol and the β_2 sympathomimetic or the β_2 sympathomimetics are mixed individually or together, if appropriate together with customary excipients or vehicles, and the mixture thus obtained is converted into suitable administration forms.

10
15
10. Use of the combination of loteprednol and at least one β_2 sympathomimetic for the production of a medicament for the simultaneous, sequential or separate treatment of allergies and/or airway disorders.

20